Pub Date : 2024-04-18DOI: 10.4274/tji.galenos.2023.85570
Y. Camcıoğlu
{"title":"Historical Perspective of Inborn Errors of Immunity in Turkey","authors":"Y. Camcıoğlu","doi":"10.4274/tji.galenos.2023.85570","DOIUrl":"https://doi.org/10.4274/tji.galenos.2023.85570","url":null,"abstract":"","PeriodicalId":41088,"journal":{"name":"Turkish Journal of Immunology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140685891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-18DOI: 10.4274/tji.galenos.2023.43265
Elif Karakoç-Aydıner
{"title":"The New Formulations of Immunoglobulin Replacement Therapies and Future Aspects","authors":"Elif Karakoç-Aydıner","doi":"10.4274/tji.galenos.2023.43265","DOIUrl":"https://doi.org/10.4274/tji.galenos.2023.43265","url":null,"abstract":"","PeriodicalId":41088,"journal":{"name":"Turkish Journal of Immunology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140689638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-18DOI: 10.4274/tji.galenos.2023.52386
A. Kıykım
{"title":"STAT1/STAT3 Gain of Function and Mechanisms of Immune Dysregulation","authors":"A. Kıykım","doi":"10.4274/tji.galenos.2023.52386","DOIUrl":"https://doi.org/10.4274/tji.galenos.2023.52386","url":null,"abstract":"","PeriodicalId":41088,"journal":{"name":"Turkish Journal of Immunology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140685833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Immunophenotype, Clinical Effect, and Comparison of TNFRSF13B/TACI Mutations: A Single-Center Retrospective Cohort Study of 34 Patients","authors":"Esra Cepniler, Emin Abdullayev, Sefika Ilknur Kokcu Karadag, Alişan Yıldıran","doi":"10.4274/tji.galenos.2024.32154","DOIUrl":"https://doi.org/10.4274/tji.galenos.2024.32154","url":null,"abstract":"","PeriodicalId":41088,"journal":{"name":"Turkish Journal of Immunology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140515270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-02DOI: 10.4274/tji.galenos.2024.38258
Swaathi Ravindran, Nandhini Gunasekaran, A. James, Tharani Vijayakumar, R. Krishnan
{"title":"Immunohistochemical Approach to Evaluate and Compare the Expression of CD44 in Oral Premalignant Disorders and Oral Squamous Cell Carcinoma - A Retrospective Study","authors":"Swaathi Ravindran, Nandhini Gunasekaran, A. James, Tharani Vijayakumar, R. Krishnan","doi":"10.4274/tji.galenos.2024.38258","DOIUrl":"https://doi.org/10.4274/tji.galenos.2024.38258","url":null,"abstract":"","PeriodicalId":41088,"journal":{"name":"Turkish Journal of Immunology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140515102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01DOI: 10.4274/tji.galenos.2023.76768
Sara Tahvili, S. M. A. Froushani, R. Yaghobi
Objective: Saponin compounds, including Glycyrrhizin, can enhance immune responses. The current investigation was conducted to study the effects of alum and Glycyrrhizin Liposomes (GL) as adjuvants on the humoral and cellular responses of the immune system in mice immunized with ovalbumin (OVA). Materials and Methods: Male Balb/c mice were immunized with OVA adjuvant with alum, GL, or alum-GL combination twice at two-week intervals. Two weeks after the last immunization, the specific immune responses against OVA were assessed. Results: The adjuvant formulated with alum and GL induced a Th1 cytokine pattern against OVA, while alum alone induced a Th2 cytokine pattern. The combined adjuvant increased the potential of OVA to induce a delayed-type hypersensitivity reaction and IgG2a antibody titer compared to other groups (p<0.05). OVA-specific lymphocyte proliferation did not show significant differences among the three groups receiving adjuvant (p=0.11). Conclusion: Unlike alum, the combination of alum and GL synergistically increased the cellular and humoral immune responses after immunization with an antigen and therefore had the ability to be used as an adjuvant to induce cellular immune responses.
{"title":"Immune Response Profile Induced by Combined Alum and Glycyrrhizin Liposomes in Balb/c Mice Immunized with Ovalbumin","authors":"Sara Tahvili, S. M. A. Froushani, R. Yaghobi","doi":"10.4274/tji.galenos.2023.76768","DOIUrl":"https://doi.org/10.4274/tji.galenos.2023.76768","url":null,"abstract":"Objective: Saponin compounds, including Glycyrrhizin, can enhance immune responses. The current investigation was conducted to study the effects of alum and Glycyrrhizin Liposomes (GL) as adjuvants on the humoral and cellular responses of the immune system in mice immunized with ovalbumin (OVA). Materials and Methods: Male Balb/c mice were immunized with OVA adjuvant with alum, GL, or alum-GL combination twice at two-week intervals. Two weeks after the last immunization, the specific immune responses against OVA were assessed. Results: The adjuvant formulated with alum and GL induced a Th1 cytokine pattern against OVA, while alum alone induced a Th2 cytokine pattern. The combined adjuvant increased the potential of OVA to induce a delayed-type hypersensitivity reaction and IgG2a antibody titer compared to other groups (p<0.05). OVA-specific lymphocyte proliferation did not show significant differences among the three groups receiving adjuvant (p=0.11). Conclusion: Unlike alum, the combination of alum and GL synergistically increased the cellular and humoral immune responses after immunization with an antigen and therefore had the ability to be used as an adjuvant to induce cellular immune responses.","PeriodicalId":41088,"journal":{"name":"Turkish Journal of Immunology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72385908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01DOI: 10.4274/tji.galenos.2023.88700
H. Al-Madhagi
Objective: More than 3 million individuals globally suffer from systemic lupus erythematosus (SLE) with no radical therapy for such a multi-organ disease. The present in silico study explores the virtual repurposing of certain monoclonal antibodies (mAb) against the emerging target toll-like receptor 7 (TLR-7). Materials and Methods: The 3D structure of TLR-7 and the shortlisted mAb were retrieved from Alphafold and Thera-SabDab datasets, which were then subjected to docking by pyDockWEB and HDOCK webservers. Molecular dynamics (MD) simulations and MM/GBSA were also predicted for the best docked complex. Results: Bevacizumab was the best potential antagonist mAb of human TLR-7 in terms of protein docking. MD simulations unveiled the stability and the flexibility of the docked complex and MM/GBSA predicted the hotspot residues of the TLR-7-Bevacizumab. Conclusion: Bevacizumab can be deemed as potential repurposed mAb for treating SLE in silico , which needs experimental validation.
{"title":"Computational Repurposing of Certain Monoclonal Antibodies for the Treatment of Systemic Lupus Erythematosus","authors":"H. Al-Madhagi","doi":"10.4274/tji.galenos.2023.88700","DOIUrl":"https://doi.org/10.4274/tji.galenos.2023.88700","url":null,"abstract":"Objective: More than 3 million individuals globally suffer from systemic lupus erythematosus (SLE) with no radical therapy for such a multi-organ disease. The present in silico study explores the virtual repurposing of certain monoclonal antibodies (mAb) against the emerging target toll-like receptor 7 (TLR-7). Materials and Methods: The 3D structure of TLR-7 and the shortlisted mAb were retrieved from Alphafold and Thera-SabDab datasets, which were then subjected to docking by pyDockWEB and HDOCK webservers. Molecular dynamics (MD) simulations and MM/GBSA were also predicted for the best docked complex. Results: Bevacizumab was the best potential antagonist mAb of human TLR-7 in terms of protein docking. MD simulations unveiled the stability and the flexibility of the docked complex and MM/GBSA predicted the hotspot residues of the TLR-7-Bevacizumab. Conclusion: Bevacizumab can be deemed as potential repurposed mAb for treating SLE in silico , which needs experimental validation.","PeriodicalId":41088,"journal":{"name":"Turkish Journal of Immunology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72421936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-01DOI: 10.4274/tji.galenos.2023.81894
Sayali Rajendra Kale, Pallavi Patil
Idiopathic thrombocytopenic purpura (ITP) is characterized by immunologic destruction of platelets and normal/enlarged megakaryocytes in the bone marrow. ITP is broken down into acute and chronic variants. Acute forms cause significant bleeding, whereas chronic forms develop slowly and exhibit minimal to no symptoms. Body makes antibodies that are directed against its own platelets, which can lead to internal bleeding, thrombocytopenic purpura, and petechiae. Immunosuppressants, thrombopoietin receptor agonists, corticosteroids, intravenous immunoglobulins, anti-D immunoglobulin, rituximab, and splenectomy are among the treatments for chronic ITP. Around two thirds of patients benefit from existing treatments; however, some sufferers are resistant to them or do not respond to them over the long term. According to Ayurveda scriptures, ITP is related to Tiryaga Raktapitta because all of the Doshas are vitiated, flowing in the blood and manifesting subcutaneously.
{"title":"Ayurveda and Allopathic Therapeutic Strategies in Immune Thrombocytopenic Purpura: An Overview","authors":"Sayali Rajendra Kale, Pallavi Patil","doi":"10.4274/tji.galenos.2023.81894","DOIUrl":"https://doi.org/10.4274/tji.galenos.2023.81894","url":null,"abstract":"Idiopathic thrombocytopenic purpura (ITP) is characterized by immunologic destruction of platelets and normal/enlarged megakaryocytes in the bone marrow. ITP is broken down into acute and chronic variants. Acute forms cause significant bleeding, whereas chronic forms develop slowly and exhibit minimal to no symptoms. Body makes antibodies that are directed against its own platelets, which can lead to internal bleeding, thrombocytopenic purpura, and petechiae. Immunosuppressants, thrombopoietin receptor agonists, corticosteroids, intravenous immunoglobulins, anti-D immunoglobulin, rituximab, and splenectomy are among the treatments for chronic ITP. Around two thirds of patients benefit from existing treatments; however, some sufferers are resistant to them or do not respond to them over the long term. According to Ayurveda scriptures, ITP is related to Tiryaga Raktapitta because all of the Doshas are vitiated, flowing in the blood and manifesting subcutaneously.","PeriodicalId":41088,"journal":{"name":"Turkish Journal of Immunology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82699017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：